Vincent M. Crowley

1.9k total citations · 1 hit paper
22 papers, 1.1k citations indexed

About

Vincent M. Crowley is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Vincent M. Crowley has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Organic Chemistry. Recurrent topics in Vincent M. Crowley's work include Heat shock proteins research (11 papers), Peptidase Inhibition and Analysis (7 papers) and Click Chemistry and Applications (5 papers). Vincent M. Crowley is often cited by papers focused on Heat shock proteins research (11 papers), Peptidase Inhibition and Analysis (7 papers) and Click Chemistry and Applications (5 papers). Vincent M. Crowley collaborates with scholars based in United States, Germany and Japan. Vincent M. Crowley's co-authors include Benjamin F. Cravatt, Melissa M. Dix, Thomas Wucherpfennig, Xiaoyu Zhang, Brian S. J. Blagg, Anuj Khandelwal, Raquel L. Lieberman, Dustin J. E. Huard, Radu M. Suciu and Sanket J. Mishra and has published in prestigious journals such as Journal of the American Chemical Society, Angewandte Chemie International Edition and Cancer Research.

In The Last Decade

Vincent M. Crowley

22 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16

2019 324 citations Xiaoyu Zhang, Vincent M. Crowley et al. Nature Chemical Biology profile →

Peers

Countries citing papers authored by Vincent M. Crowley

Since Specialization

Citations

This map shows the geographic impact of Vincent M. Crowley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent M. Crowley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent M. Crowley more than expected).

Fields of papers citing papers by Vincent M. Crowley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent M. Crowley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent M. Crowley. The network helps show where Vincent M. Crowley may publish in the future.

Co-authorship network of co-authors of Vincent M. Crowley

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent M. Crowley. A scholar is included among the top collaborators of Vincent M. Crowley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent M. Crowley. Vincent M. Crowley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Elucidation of novel TRAP1-Selective inhibitors that regulate mitochondrial processes 2023 ·European Journal of Medicinal Chemistry ·(unknown), Shuxia Peng, (unknown), Vincent M. Crowley, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Junpeng Deng, Robert L. Matts, Brian S. J. Blagg	11
2	Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer 2023 ·iScience ·Nada H. Eisa, Vincent M. Crowley, Asif Elahi, (unknown), (unknown), (unknown), Sumin Lu, (unknown), (unknown), Daniela Marasco, Abdeljabar El Andaloussi, Sukyeong Lee, Francis Tsai, Paulo C. Rodrı́guez, David H. Munn, Esteban Celis, (unknown), Abdessamad Debbab, Brian S. J. Blagg, Ahmed Chadli	11
3	Abstract 2272: Targeting the chaperone Hsp90 to activate the immune system and eradicate the triple negative breast cancer 2023 ·Cancer Research ·Nada H. Eisa, Vincent M. Crowley, Asif Elahi, (unknown), (unknown), Abdessamad Debbab, Brian S. J. Blagg, Ahmed Chadli	1
4	Enniatin A Analogues as Novel Hsp90 Inhibitors that Modulate Triple-Negative Breast Cancer 2023 ·ACS Medicinal Chemistry Letters ·(unknown), Vincent M. Crowley, (unknown), (unknown), Asif Elahi, (unknown), Ahmed Chadli, Brian S. J. Blagg	4
5	Chemical proteomic identification of functional cysteines with atypical electrophile reactivities 2021 ·Tetrahedron Letters ·(unknown), Vincent M. Crowley, Radu M. Suciu, Dale L. Boger, Benjamin F. Cravatt	7
6	A proteome-wide atlas of lysine-reactive chemistry 2021 ·Nature Chemistry ·Mikail E. Abbasov, Madeline E. Kavanagh, Taka-Aki Ichu, Michael R. Lazear, Yongfeng Tao, Vincent M. Crowley, Christopher W. am Ende, Stephan M. Hacker, (unknown), Melissa M. Dix, Radu M. Suciu, Matthew M. Hayward, Laura L. Kiessling, Benjamin F. Cravatt	156
7	DCAF11 Supports Targeted Protein Degradation by Electrophilic Proteolysis-Targeting Chimeras 2021 ·Journal of the American Chemical Society ·Xiaoyu Zhang, (unknown), Christie L. Eissler, Vincent M. Crowley, Yu Yamashita, Michael A. Schafroth, (unknown), David S. Weinstein, Kent T. Symons, Brian E. Nordin, (unknown), Thomas Wucherpfennig, (unknown), Melissa M. Dix, Dean Stamos, Todd M. Kinsella, Gabriel M. Simon, Kristen A. Baltgalvis, Benjamin F. Cravatt	119
8	Functionalized Scout Fragments for Site-Specific Covalent Ligand Discovery and Optimization 2021 ·ACS Central Science ·Vincent M. Crowley, Marvin Thielert, Benjamin F. Cravatt	35
9	Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16 breakdown → 2019 ·Nature Chemical Biology ·Xiaoyu Zhang, Vincent M. Crowley, Thomas Wucherpfennig, Melissa M. Dix, Benjamin F. Cravatt	324
10	The Proteome‐Wide Potential for Reversible Covalency at Cysteine 2019 ·Angewandte Chemie ·(unknown), Ekaterina V. Vinogradova, Radu M. Suciu, Vincent M. Crowley, Balyn W. Zaro, J. Michael Bradshaw, Ken A. Brameld, Benjamin F. Cravatt	6
11	The Proteome‐Wide Potential for Reversible Covalency at Cysteine 2019 ·Angewandte Chemie International Edition ·(unknown), Ekaterina V. Vinogradova, Radu M. Suciu, Vincent M. Crowley, Balyn W. Zaro, J. Michael Bradshaw, Ken A. Brameld, Benjamin F. Cravatt	44
12	Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding 2018 ·Journal of Medicinal Chemistry ·Nanette L. S. Que, Vincent M. Crowley, Adam S. Duerfeldt, Jinbo Zhao, (unknown), Brian S. J. Blagg, D.T. Gewirth	37
13	Trifunctional High-Throughput Screen Identifies Promising Scaffold To Inhibit Grp94 and Treat Myocilin-Associated Glaucoma 2018 ·ACS Chemical Biology ·Dustin J. E. Huard, Vincent M. Crowley, Yuhong Du, (unknown), (unknown), (unknown), Chad A. Dickey, John Koren, Laura J. Blair, Haian Fu, Brian S. J. Blagg, Raquel L. Lieberman	22
14	Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma 2017 ·Scientific Reports ·Andrew R. Stothert, (unknown), Xiaolan Tang, Vincent M. Crowley, Sanket J. Mishra, Jack M. Webster, Bryce A. Nordhues, Dustin J. E. Huard, Christopher L. Passaglia, Raquel L. Lieberman, Brian S. J. Blagg, Laura J. Blair, John Koren, Chad A. Dickey	25
15	Second Generation Grp94‐Selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer 2017 ·Chemistry - A European Journal ·Vincent M. Crowley, Dustin J. E. Huard, Raquel L. Lieberman, Brian S. J. Blagg	39
16	Resorcinol-Based Grp94-Selective Inhibitors 2017 ·ACS Medicinal Chemistry Letters ·Anuj Khandelwal, Vincent M. Crowley, Brian S. J. Blagg	29
17	Natural Product Inspired N‐Terminal Hsp90 Inhibitors: From Bench to Bedside? 2015 ·Medicinal Research Reviews ·Anuj Khandelwal, Vincent M. Crowley, Brian S. J. Blagg	83
18	Exploiting the interaction between Grp94 and aggregated myocilin to treat glaucoma 2014 ·Human Molecular Genetics ·Andrew R. Stothert, (unknown), Dustin J. E. Huard, Sarah N. Fontaine, Vincent M. Crowley, Sanket J. Mishra, Brian S. J. Blagg, Raquel L. Lieberman, Chad A. Dickey	39
19	Development of radamide analogs as Grp94 inhibitors 2014 ·Bioorganic & Medicinal Chemistry ·Aaron Muth, Vincent M. Crowley, Anuj Khandelwal, Sanket J. Mishra, Jinbo Zhao, Jessica A. Hall, Brian S. J. Blagg	24
20	An Efficient Synthesis of 4(5)-Benzyl-l-histidines Employing Catalytic Transfer Hydrogenolysis at Elevated Temperatures 2013 ·Synthesis ·David Smith, Audrey T. Gallagher, Vincent M. Crowley, (unknown), Peter W. Abel, Martin Hulce	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact